ABSTRACT A critical barrier to codevelopment of tuberculosis (TB) regimens is a limited
ability to identify optimal drug and dose combinations in early-phase clinical testing. While …

Bedaquiline is a diarylquinoline antimycobacterial drug and a key component of several
regimens in clinical development for the treatment of tuberculosis (TB) but with ongoing …

Background Site-of-action concentrations for bedaquiline and pretomanid from tuberculosis
patients are unavailable. The objective of this work was to predict bedaquiline and …

Rationale: New regimens to shorten tuberculosis treatment and manage patients with drug-
resistant tuberculosis who are infected with HIV are urgently needed. Experimental and …

ABSTRACT A major challenge for tuberculosis (TB) drug development is to prioritize
promising combination regimens from a large and growing number of possibilities. This …

Aims Bedaquiline, pretomanid and linezolid (BPaL) combination treatment against
Mycobacterium tuberculosis is promising, yet safety and adherence concerns exist that …

Short-course regimens for multidrug-resistant tuberculosis (MDR-TB) are urgently needed.
Limited data suggest that the new drug bedaquiline (BDQ) may have the potential to shorten …

New regimens based on 2 or more novel agents are sought to shorten or to simplify
treatment of tuberculosis (TB), including drug-resistant forms. Prior studies showed that the …

Aims Despite evidence of the efficacy of anti‐tubercular drug regimens in clinical practice,
the rationale underpinning the selection of doses and companion drugs for combination …

Novel regimens combining bedaquiline and pretomanid with either linezolid (BPaL regimen)
or moxifloxacin and pyrazinamide (BPaMZ regimen) shorten the treatment duration needed …